B+
Bull case
25%
Probability
Target price
$380.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NTRA
NateraBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$335.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$270.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+64.0
Score
AI commentary
News tone is positive after the Q2 release, with secondary coverage reporting fresh 52-week highs and an unusually strong session. A secondary analyst listing reports a TD Cowen target increase to $325 from $280, but broader post-print ratings, target changes, and estimate revisions are unavailable. Social, options, short-interest, and employee-sentiment data were not available; missing data is not treated as positive evidence. Insider selling adds a modest near-term caution signal [#SEC-FORM4-2026-08-07].
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-06eventQ2 2026 results and raised revenue outlookHigh impact
Natera reported Q2 revenue of $752.8 million, up 37.7% year over year, processed approximately 1.04 million tests, and raised 2026 revenue guidance by $100 million at the midpoint to $2.85-$2.91 billion [#SEC-8K-2026-08-06].
2026-08-07catalystPost-earnings momentum versus valuation digestionMedium impact
Recent secondary coverage described fresh 52-week highs and Natera's strongest day in nearly 20 months after the release, creating momentum but also increasing pullback sensitivity. The stock is at $322.10 versus the available median analyst target of $317.33.
2026-08-11catalystInsider selling as near-term supply riskHigh impact
Form 4 filings reported open-market sales by Executive Chairman Matthew Rabinowitz and co-founder Jonathan Sheena on August 7; this is a trading-risk signal only and is not evidence about operating performance [#SEC-FORM4-2026-08-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology